Thoracic Surgery Branch: Clinical Trials
-
Phase I/II Evaluation of Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients with Unresectable Pulmonary Metastases from Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0004Investigator David S. Schrump, M.D., M.B.A., F.A.C.S. -
Prospective Evaluation of Photon Counting Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition Syndrome
Open - RecruitingNCI Protocol ID NCI-20-C-0106Investigator David S. Schrump, M.D., M.B.A., F.A.C.S. -
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Open - RecruitingNCI Protocol ID NCI-17-C-0140Investigator David S. Schrump, M.D., M.B.A., F.A.C.S. -
Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms with Pleuropulmonary Metastases
Open - RecruitingNCI Protocol ID NCI-16-C-0152Investigator David S. Schrump, M.D., M.B.A., F.A.C.S. -
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies
Open - RecruitingNCI Protocol ID NCI-06-C-0014Investigator David S. Schrump, M.D., M.B.A., F.A.C.S.